John Oas

John Oas, MD

  • Neurology

Appointments: (614) 293-4969

Specialties and conditions I treat

  • Neurology
  • Neurotology
  • Meniere Disease
  • Labyrinthitis
  • Vertigo
  • Vestibular Neuronitis
  • Migraine Disorders
  • Dizziness
  • Vestibular Diseases
  • Arnold-Chiari Malformation

Locations where I practice

Please note: Not all physicians schedule patients at each listed location. Please call the “Schedule an appointment” number shown above for scheduling assistance.

Education and training

Medical Degree

M.D.
University of Texas Medical Branch
5/31/1986

Residency

Neurology
University of Texas Medical Branch
7/1/1987 - 6/30/1990

More about my work

My background

Fellowship

Neurotology
UCLA Medical Center
7/1/1990 - 6/30/1992

Board Certification

American Board of Psychiatry & Neurology (Subspecialty: Neurology)
11/8/1994

My Department

Neurology

Reviews

139 Patient Satisfaction Reviews

The patient satisfaction rating is an average of all responses to the six doctor communication related questions shown below from the Clinician and Group Consumer Assessment of Healthcare Providers and Systems survey. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page
  • Overall
    4.3 out of 5
  • Explains Things Clearly 4.1
  • Listens Carefully 4.2
  • Gives Understandable Instructions 4.2
  • Knows My Medical History 4.3
  • Shows Respect 4.2
  • Time Spent Together 4.7

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.

As of 03/28/2017, Dr. Oas has reported no financial relationships with medical device, research and/or drug companies.